Published in J Clin Invest on October 01, 2005
GPIHBP1: an endothelial cell molecule important for the lipolytic processing of chylomicrons. Curr Opin Lipidol (2007) 2.01
Molecular processes that handle -- and mishandle -- dietary lipids. J Clin Invest (2008) 1.60
Post-heparin LPL activity measurement using VLDL as a substrate: a new robust method for routine assessment of plasma triglyceride lipolysis defects. PLoS One (2014) 1.41
Give me A5 for lipoprotein hydrolysis! J Clin Invest (2005) 1.07
Novel LMF1 nonsense mutation in a patient with severe hypertriglyceridemia. J Clin Endocrinol Metab (2009) 0.98
Intracellular lipid droplet targeting by apolipoprotein A-V requires the carboxyl-terminal segment. J Lipid Res (2008) 0.97
Intravenous injection of apolipoprotein A-V reconstituted high-density lipoprotein decreases hypertriglyceridemia in apoav-/- mice and requires glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1. Arterioscler Thromb Vasc Biol (2010) 0.93
Biogenesis of apolipoprotein A-V and its impact on VLDL triglyceride secretion. J Lipid Res (2010) 0.92
The role of CREB-H transcription factor in triglyceride metabolism. Curr Opin Lipidol (2012) 0.90
Interactions between the APOA5 -1131T>C and the FEN1 10154G>T polymorphisms on ω6 polyunsaturated fatty acids in serum phospholipids and coronary artery disease. J Lipid Res (2010) 0.87
Apoprotein A-V: an important regulator of triglyceride metabolism. J Inherit Metab Dis (2008) 0.87
An APOA5 3' UTR variant associated with plasma triglycerides triggers APOA5 downregulation by creating a functional miR-485-5p binding site. Am J Hum Genet (2014) 0.86
Determinants of plasma apolipoprotein A-V and APOA5 gene transcripts in humans. J Intern Med (2008) 0.85
Influence of apolipoprotein A-V on the metabolic fate of triacylglycerol. Curr Opin Lipidol (2013) 0.84
Apolipoprotein A5 and lipoprotein lipase interact to modulate anthropometric measures in Hispanics of Caribbean origin. Obesity (Silver Spring) (2009) 0.83
The N-terminus of apolipoprotein A-V adopts a helix bundle molecular architecture. Biochemistry (2008) 0.83
Association of APOA5 rs662799 and rs3135506 polymorphisms with arterial hypertension in Moroccan patients. Lipids Health Dis (2014) 0.82
Evaluation of seven common lipid associated loci in a large Indian sib pair study. Lipids Health Dis (2012) 0.82
Lipoprotein lipase activity and mass, apolipoprotein C-II mass and polymorphisms of apolipoproteins E and A5 in subjects with prior acute hypertriglyceridaemic pancreatitis. BMC Gastroenterol (2009) 0.81
Apolipoprotein A-V gene therapy for disease prevention / treatment: a critical analysis. J Biomed Res (2015) 0.80
Gene transfer of apolipoprotein A-V improves the hypertriglyceridemic phenotype of apoa5 (-/-) mice. Arterioscler Thromb Vasc Biol (2013) 0.79
Apolipoprotein A-V N-terminal domain lipid interaction properties in vitro explain the hypertriglyceridemic phenotype associated with natural truncation mutants. J Biol Chem (2009) 0.79
Structural and functional analysis of APOA5 mutations identified in patients with severe hypertriglyceridemia. J Lipid Res (2013) 0.78
Dietary oxidized linoleic acid lowers triglycerides via APOA5/APOClll dependent mechanisms. Atherosclerosis (2008) 0.78
The pathophysiology of intestinal lipoprotein production. Front Physiol (2015) 0.77
The carboxyl-terminal segment of apolipoprotein A-V undergoes a lipid-induced conformational change. Biochemistry (2010) 0.77
Association of APOA5 T1131C polymorphism and risk of coronary artery disease. Int J Clin Exp Med (2015) 0.76
Association between CETP, MLXIPL, and TOMM40 polymorphisms and serum lipid levels in a Latvian population. Meta Gene (2014) 0.76
ApoE2-associated hypertriglyceridemia is ameliorated by increased levels of apoA-V but unaffected by apoC-III deficiency. J Lipid Res (2008) 0.76
APOA5 Q97X mutation identified through homozygosity mapping causes severe hypertriglyceridemia in a Chilean consanguineous family. BMC Med Genet (2012) 0.75
Type 1 hyperlipoproteinemia and recurrent acute pancreatitis due to lipoprotein lipase antibody in a young girl with Sjogren's syndrome. J Clin Endocrinol Metab (2011) 0.75
The APOA5 rs662799 polymorphism is associated with dyslipidemia and the severity of coronary heart disease in Chinese women. Lipids Health Dis (2016) 0.75
Effects of APOA5 S19W polymorphism on growth, insulin sensitivity and lipoproteins in normoweight neonates. Eur J Pediatr (2011) 0.75
An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science (2001) 8.73
Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk (1996) 6.18
Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Hum Mol Genet (2002) 2.71
SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies. Metabolism (1998) 2.65
Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet (2002) 2.27
Hyperlipidemia in patients with apolipoprotein E 2/2 phenotype: apolipoprotein A5 S19W mutation as a cofactor. Clin Chem (2004) 2.23
Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem (2005) 2.07
ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis. J Biol Chem (2004) 1.81
Apolipoprotein A-V: a novel apolipoprotein associated with an early phase of liver regeneration. J Biol Chem (2001) 1.69
Hyperlipidemia and pancreatitis during pregnancy in two sisters with a mutation in the lipoprotein lipase gene. Ann Intern Med (1996) 1.56
Apolipoprotein A-V-heparin interactions: implications for plasma lipoprotein metabolism. J Biol Chem (2005) 1.55
Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem Biophys Res Commun (2004) 1.53
The genetic effect of the apoprotein AV gene on the serum triglyceride level in Japanese. Atherosclerosis (2002) 1.37
Adenoviral overexpression of apolipoprotein A-V reduces serum levels of triglycerides and cholesterol in mice. Biochem Biophys Res Commun (2002) 1.32
Genetic analysis of a polymorphism in the human apoA-V gene: effect on plasma lipids. J Lipid Res (2003) 1.32
Inherited apolipoprotein A-V deficiency in severe hypertriglyceridemia. Arterioscler Thromb Vasc Biol (2004) 1.31
Measurement of muscle protein fractional synthetic rate by capillary gas chromatography/combustion isotope ratio mass spectrometry. Biol Mass Spectrom (1992) 1.28
Structure and interfacial properties of human apolipoprotein A-V. J Biol Chem (2003) 1.27
Acquired hyperlipidemia (secondary dyslipoproteinemias). Endocrinol Metab Clin North Am (1990) 1.20
Linkage and association between distinct variants of the APOA1/C3/A4/A5 gene cluster and familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol (2003) 1.17
Haplotype analysis of the apolipoprotein gene cluster on human chromosome 11. Genomics (2004) 1.17
Association found between the promoter region polymorphism in the apolipoprotein A-V gene and the serum triglyceride level in Japanese schoolchildren. Hum Genet (2002) 1.15
Newly identified apolipoprotein AV gene predisposes to high plasma triglycerides in familial combined hyperlipidemia. Clin Chem (2002) 1.11
Tracer-to-tracee ratio for analysis of stable isotope tracer data: link with radioactive kinetic formalism. Am J Physiol (1992) 1.11
APOA5-1131T>C polymorphism is associated with triglyceride levels in Chinese men. Clin Genet (2003) 1.10
Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: a stable isotope kinetic study. Eur J Clin Invest (2000) 1.04
T-1131-->C polymorphism within the apolipoprotein AV gene in hypertriglyceridemic individuals. Atherosclerosis (2003) 1.03
High frequency of mutations in the human lipoprotein lipase gene in pregnancy-induced chylomicronemia: possible association with apolipoprotein E2 isoform. J Lipid Res (1994) 1.02
Postprandial regulation of blood lipids and adipose tissue lipoprotein lipase in type 2 diabetes patients and healthy control subjects. Atherosclerosis (2003) 0.96
Genetic variants in Apolipoprotein AV alter triglyceride concentrations in pregnancy. Lipids Health Dis (2003) 0.89
Severe hypertriglyceridaemia in Type II diabetes: involvement of apoC-III Sst-I polymorphism, LPL mutations and apo E3 deficiency. Diabetologia (2000) 0.88
Early kinetic abnormalities of apoB-containing lipoproteins in insulin-resistant women with abdominal obesity. Arterioscler Thromb Vasc Biol (2002) 0.86
Significant improvement of apolipoprotein B-containing lipoprotein metabolism by insulin treatment in patients with non-insulin-dependent diabetes mellitus. Diabetologia (2000) 0.85
Alteration in lipoprotein lipase activity bound to triglyceride-rich lipoproteins in the postprandial state in type 2 diabetes. J Lipid Res (2004) 0.85
Effect of insulin therapy on metabolic fate of apolipoprotein B-containing lipoproteins in NIDDM. Diabetes (1990) 0.85
Isotope ratio mass spectrometry, compared with conventional mass spectrometry in kinetic studies at low and high enrichment levels: application to lipoprotein kinetics. Anal Biochem (1997) 0.85
Lipoprotein lipase activity and serum lipoproteins in untreated type 2 (insulin-independent) diabetes associated with obesity. Diabetologia (1982) 0.83
Ex vivo measurement of lipoprotein lipase-dependent very low density lipoprotein (VLDL)-triglyceride hydrolysis in human VLDL: an alternative to the postheparin assay of lipoprotein lipase activity? J Clin Endocrinol Metab (2001) 0.83
Characterization of a new case of autoimmune type I hyperlipidemia: long-term remission under immunosuppressive therapy. J Clin Endocrinol Metab (1997) 0.82
In vivo metabolism of apolipoprotein A-IV in severe hypertriglyceridemia: a combined radiotracer and stable isotope kinetic study. J Lipid Res (1994) 0.79
A common allele on chromosome 9 associated with coronary heart disease. Science (2007) 20.37
ChIP-seq accurately predicts tissue-specific activity of enhancers. Nature (2009) 18.38
Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med (2005) 15.18
Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat Genet (2007) 13.78
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet (2003) 11.67
Most rare missense alleles are deleterious in humans: implications for complex disease and association studies. Am J Hum Genet (2007) 10.92
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet (2008) 10.87
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
The amphioxus genome and the evolution of the chordate karyotype. Nature (2008) 8.03
VISTA Enhancer Browser--a database of tissue-specific human enhancers. Nucleic Acids Res (2006) 7.04
Metagenomic discovery of biomass-degrading genes and genomes from cow rumen. Science (2011) 6.93
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med (2007) 6.31
Genomic views of distant-acting enhancers. Nature (2009) 6.27
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet (2006) 5.67
Medical sequencing at the extremes of human body mass. Am J Hum Genet (2007) 5.61
Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J Clin Invest (2008) 5.05
Deletion of ultraconserved elements yields viable mice. PLoS Biol (2007) 4.81
Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nat Genet (2006) 4.68
Massively parallel functional dissection of mammalian enhancers in vivo. Nat Biotechnol (2012) 4.51
ChIP-Seq identification of weakly conserved heart enhancers. Nat Genet (2010) 4.32
Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proc Natl Acad Sci U S A (2008) 4.13
Disruption of an AP-2alpha binding site in an IRF6 enhancer is associated with cleft lip. Nat Genet (2008) 4.04
Close sequence comparisons are sufficient to identify human cis-regulatory elements. Genome Res (2006) 3.92
Human-specific gain of function in a developmental enhancer. Science (2008) 3.84
Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature (2010) 3.77
Ultraconservation identifies a small subset of extremely constrained developmental enhancers. Nat Genet (2008) 3.55
Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J Clin Invest (2006) 3.48
Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet (2007) 3.47
Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care (2006) 3.37
The amphioxus genome illuminates vertebrate origins and cephalochordate biology. Genome Res (2008) 3.04
Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants. Proc Natl Acad Sci U S A (2013) 2.93
Large-scale discovery of enhancers from human heart tissue. Nat Genet (2011) 2.70
Combinatorial regulation of endothelial gene expression by ets and forkhead transcription factors. Cell (2008) 2.60
Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. Nat Genet (2009) 2.57
The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice. J Biol Chem (2006) 2.38
A high-resolution enhancer atlas of the developing telencephalon. Cell (2013) 2.34
Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes (2005) 2.32
The DNA sequence and biology of human chromosome 19. Nature (2004) 2.29
Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet (2002) 2.27
Plasma fatty acid composition is associated with the metabolic syndrome and low-grade inflammation in overweight adolescents. Am J Clin Nutr (2005) 2.17
Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res (2004) 2.16
Fine tuning of craniofacial morphology by distant-acting enhancers. Science (2013) 2.16
Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J Am Coll Cardiol (2006) 2.15
Increased ABCA1 activity protects against atherosclerosis. J Clin Invest (2002) 2.13
Homotypic clusters of transcription factor binding sites are a key component of human promoters and enhancers. Genome Res (2010) 2.12
Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem (2005) 2.07
Apolipoprotein A-V deficiency results in marked hypertriglyceridemia attributable to decreased lipolysis of triglyceride-rich lipoproteins and removal of their remnants. Arterioscler Thromb Vasc Biol (2005) 2.06
Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: the PRIME Study. Atherosclerosis (2003) 2.02
Functional variants of the HMGA1 gene and type 2 diabetes mellitus. JAMA (2011) 2.00
C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol (2003) 1.99
Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation (2004) 1.98
Phylo-VISTA: interactive visualization of multiple DNA sequence alignments. Bioinformatics (2004) 1.97
Genome resequencing reveals multiscale geographic structure and extensive linkage disequilibrium in the forest tree Populus trichocarpa. New Phytol (2012) 1.88
Dlx1&2-dependent expression of Zfhx1b (Sip1, Zeb2) regulates the fate switch between cortical and striatal interneurons. Neuron (2013) 1.87
The farnesoid X receptor modulates hepatic carbohydrate metabolism during the fasting-refeeding transition. J Biol Chem (2005) 1.85
Reverse osmosis desalination: water sources, technology, and today's challenges. Water Res (2009) 1.80
Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest (2002) 1.80
Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta (2007) 1.79
Anxiety and depression are associated with unhealthy lifestyle in patients at risk of cardiovascular disease. Atherosclerosis (2005) 1.78
Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci (2003) 1.78
The orphan nuclear receptor Rev-Erbalpha is a peroxisome proliferator-activated receptor (PPAR) gamma target gene and promotes PPARgamma-induced adipocyte differentiation. J Biol Chem (2003) 1.76
Peroxisome proliferator-activated receptor alpha induces NADPH oxidase activity in macrophages, leading to the generation of LDL with PPAR-alpha activation properties. Circ Res (2004) 1.72
A restricted spectrum of NRAS mutations causes Noonan syndrome. Nat Genet (2009) 1.71
Identification of Rev-erbalpha as a physiological repressor of apoC-III gene transcription. J Lipid Res (2002) 1.71
Associations between anxiety, depression, and the metabolic syndrome. Biol Psychiatry (2007) 1.70
Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat Med (2005) 1.69
PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia. Arterioscler Thromb Vasc Biol (2005) 1.68
A comparison of the NCEP-ATPIII, IDF and AHA/NHLBI metabolic syndrome definitions with relation to early carotid atherosclerosis in subjects with hypercholesterolemia or at risk of CVD: evidence for sex-specific differences. Atherosclerosis (2006) 1.66
Characterization of the human PPARalpha promoter: identification of a functional nuclear receptor response element. Mol Endocrinol (2002) 1.63
Glucose regulates the expression of the farnesoid X receptor in liver. Diabetes (2004) 1.63
Transcriptional regulation of apolipoprotein A5 gene expression by the nuclear receptor RORalpha. Arterioscler Thromb Vasc Biol (2005) 1.63
Atherogenic lipoprotein particles in atherosclerosis. Circulation (2004) 1.63
Lack of MEF2A mutations in coronary artery disease. J Clin Invest (2005) 1.62
The DNA sequence and comparative analysis of human chromosome 5. Nature (2004) 1.62
Comparative genomic analysis as a tool for biological discovery. J Physiol (2004) 1.61
Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol (2003) 1.60
Directed evolution of ionizing radiation resistance in Escherichia coli. J Bacteriol (2009) 1.60
Lack of support for the association between GAD2 polymorphisms and severe human obesity. PLoS Biol (2005) 1.59
PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. J Clin Invest (2005) 1.58
Noninvasive measurement of carotid extra-media thickness: associations with cardiovascular risk factors and intima-media thickness. JACC Cardiovasc Imaging (2009) 1.58
Enhancer identification through comparative genomics. Semin Cell Dev Biol (2007) 1.56
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression. Gastroenterology (2003) 1.54
Perilipin, a potential substitute for adipophilin in triglyceride storage in human macrophages. Atherosclerosis (2006) 1.54
Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochem Biophys Res Commun (2004) 1.53
Identification of novel craniofacial regulatory domains located far upstream of SOX9 and disrupted in Pierre Robin sequence. Hum Mutat (2014) 1.53
Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest (2005) 1.49
In vivo characterization of a vertebrate ultraconserved enhancer. Genomics (2005) 1.49
Adipophilin enhances lipid accumulation and prevents lipid efflux from THP-1 macrophages: potential role in atherogenesis. Arterioscler Thromb Vasc Biol (2004) 1.48
Implications of emerging risk factors for therapeutic intervention. Nutr Metab Cardiovasc Dis (2005) 1.43
Lipoprotein (a) as a predictor of coronary heart disease: the PRIME Study. Atherosclerosis (2002) 1.41
Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat Clin Pract Endocrinol Metab (2007) 1.41
Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs. Arch Cardiovasc Dis (2009) 1.40
The sequence and analysis of duplication-rich human chromosome 16. Nature (2004) 1.38
Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J Biol Chem (2002) 1.36
Tissue-specific roles of ABCA1 influence susceptibility to atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 1.36